Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
Stable profits, low leverage to keep credit profiles comfortable
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
A new initiative to contribute to enhancing drug discovery capabilities in the field of gene and cell therapy in Japan
Konieczny has served as Interim CEO since April 2024
He will lead the final stages of work to commission the 54,000-square-foot facility and then lead ongoing operations at the site
New Phase II data show vast majority of patients experiencing no relapses or disability progression
Phase 3 study results will form the basis for future discussions with global regulatory authorities
Subscribe To Our Newsletter & Stay Updated
